1. |
TRAVIS R C, KEY T J. Oestrogen exposure and breast cancer risk[J]. Breast Cancer Res,2003,5(5):239-247..
|
2. |
PIKE M C, SPICER D V, DAHMOUSH L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk[J]. Epidemiol Rev,1993,15(1):17-20..
|
3. |
楊才明, 夏淑君.HER2 2/neu基因蛋白、BRCA1和BRCA2基因突變檢測在乳腺癌診斷和治療中的臨床意義[J].標記免疫分析與臨床,2005,12(1):43-45..
|
4. |
WILEY S R, SCHOOLEY K, SMOLAK P J, et al. Indentification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity,1995,3(6):673-682..
|
5. |
ASHKENAZI A, PAI R C, FONG S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[J]. J Clin Invest,1999,104(2):155-162..
|
6. |
張玉松,傅晉祥,周麗英,等.腫瘤壞死因子相關凋亡誘導配體與赫賽汀聯用對C-erbB2過表達的乳腺癌SKBR3細胞株的影響[J]. 蘇州大學學報,2007,27(1):38-40..
|
7. |
YAGER J D, DAVIDSON N E. Estrogen carcinogenesis in breast cancer[J]. N Engl J Med,2006,354:270-282..
|
8. |
SAUNDERS P T, MILLAR M R, WILLIAMS K, et al. Expression of oestrogen receptor β (ERβ1) protein in human breast cancer biopsies[J]. Br J Cancer,2002,86(2):250-256..
|
9. |
朱冉旭, 林菊生.死亡受體DR5與腫瘤細胞凋亡[J].世界華人消化雜志,2004,12(8):1909-1912.
|
10. |
馬遠方, 張軍, 趙粵萍, 等.腫瘤細胞對TRAIL敏感性與其表面DR5表達水平的相關研究[J].中華腫瘤雜志,2004,26(9):528-530..
|
11. |
李妍,曹云新,張赟,等.IFN-α對腫瘤細胞上TRAIL受體 DR4 和DR5 表達的調節及意義[J].第四軍醫大學吉林軍醫學院學報,2005,26(1):7-10.
|